 MONTREAL, Aug. 13, 2021 GLOBE NEWSWIRE -- Theratechnologies, Inc. Theratechnologies, or Company TSX: TH NASDAQ: THTX, a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today the publication of data from its preclinical research of TH1902 for the treatment of sortilin-positive triple negative breast cancer TNBC in the peer-reviewed journal Cancer Science, confirming the in vivo efficacy and safety of TH1902 against TNBC through a SORT1 receptor-mediated mechanism. 